Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-12
2011-07-12
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S397000
Reexamination Certificate
active
07977311
ABSTRACT:
Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.
REFERENCES:
patent: 4397840 (1983-08-01), Takezawa et al.
patent: 4419446 (1983-12-01), Howley et al.
patent: 4667016 (1987-05-01), Lai et al.
patent: 4703008 (1987-10-01), Lin
patent: 4806524 (1989-02-01), Kawaguchi et al.
patent: 5041376 (1991-08-01), Gething et al.
patent: 5217881 (1993-06-01), Park
patent: 5218092 (1993-06-01), Sasaki et al.
patent: 5378808 (1995-01-01), D'Andrea et al.
patent: 5416071 (1995-05-01), Igari et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5541158 (1996-07-01), Vance et al.
patent: 5559093 (1996-09-01), Yoshitomi et al.
patent: 5661125 (1997-08-01), Strickland
patent: 5716644 (1998-02-01), Zale et al.
patent: 6333306 (2001-12-01), Lehmann
patent: 6340742 (2002-01-01), Burg et al.
patent: 6548653 (2003-04-01), Young et al.
patent: 6583272 (2003-06-01), Bailon
patent: 7217689 (2007-05-01), Elliott et al.
patent: 7304150 (2007-12-01), Egrie et al.
patent: 2002/0037841 (2002-03-01), Papadimitriou
patent: 2002/0115833 (2002-08-01), Burg et al.
patent: A 59145/90 (1991-01-01), None
patent: 2231192 (1998-03-01), None
patent: 2284910 (1999-09-01), None
patent: 0 148 605 (1985-07-01), None
patent: 0 267 678 (1988-05-01), None
patent: 0 357 804 (1990-03-01), None
patent: 0 370 205 (1990-05-01), None
patent: 0 428 267 (1991-05-01), None
patent: 0 640 619 (1995-03-01), None
patent: 0 640 619 (1997-07-01), None
patent: 2171303 (1986-08-01), None
patent: 2172303 (1986-08-01), None
patent: WO 89/03840 (1989-05-01), None
patent: WO 90/14363 (1990-11-01), None
patent: WO 91/05867 (1991-05-01), None
patent: WO 95/05465 (1995-02-01), None
patent: 9709996 (1997-03-01), None
patent: WO 99/02711 (1999-01-01), None
patent: WO 99/11781 (1999-03-01), None
patent: WO 00/24893 (2000-05-01), None
patent: WO 00/61169 (2000-10-01), None
patent: WO 00/67769 (2000-11-01), None
patent: WO 00/67776 (2000-11-01), None
patent: WO 01/03737 (2001-01-01), None
Ashwell et al., “A Protein from Mammalian Liver That Specifically Binds Galactose-Terminated Glycoproteins”,Methods Enyzmol., 50: 287-288 (1978).
Boissel et al., “Erythropoietin Structure-Function Relationships”,The Biology of Hematopoiesis, pp. 227-232 (1990).
Boissel et al., “Erythropoietin Structure-Function Relationships”,J. Biol. Chem., 268: 15983-15993 (1993).
Bontempo, John A., “Formulation Development”,Development of Biopharmaceutical Parenteral Dosage Forms, by Marcel Dekker, Inc., Chapter 5, pp. 109-142 (1997).
Bradford, Marion M., “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding”,Anal. Biochem., 72: 248-254 (1976).
Briggs et al., “Hepatic Clearance of Intact and Desialylated Erythropoietin”,Am. J. Physiol., 227:1385-1388 (1974).
Broudy et al., “Recombinant Human Erythropoietin: Purification and Analysis of Carbohydrate Linkage”,Arch. Biochem. Biophys., 265: 329-336 (1988).
Burbaum et al., “Understanding Structural Relationships in Proteins of Unsolved Three-Dimensional Structure”,Proteins-Structure, Function and Genetics, 7(2): 99-111 (1990).
Burnette, W. Neal, “Western Blotting: Electrophoretic Transfer of Proteins from Sodium Dodecyl Sulfate-Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody and Radioiodinated Protein A”,Anal. Biochem., 112: 195-203 (1981).
Cheetham et al., “NMR Structure of Human Erythropoietin and a Comparison with its Receptor Bound Conformation”,Nature Structural Biology, 5(10): 861-866 (1998).
Cheng et. al., “Effective Amplication of Long Targets from Cloned Inserts and Human Genomic DNA”,Proc. Natl. Acad. Sci. USA, 91: 5695-5699 (1994).
Chern et al., “Structural Role of Amino Acids 99-110 in Recombinant Human Erythropoietin”,Eur. J. Biochem., 202: 225-229 (1991).
Chou et al., “Prediction of the Secondary Structure of Proteins from their Amino Acid Sequence”,Adv. Enzymol., 47: 45-148 (1978).
Cotes et al., “Bio-Assay of Erythropoietin in Mice Made Polycythaemic by Exposure to Air at a Reduced Pressure”,Nature, 191: 1065-1067 (1961).
Cunningham et al., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis”,Science, 244: 1081-1085 (1989).
DeLorme et al., “Role of Glycosylation on the Secretion and Biological Activity of Erythropoietin”,Biochemistry, 31: 9871-9876 (1992).
Davis et al., “Characterization of Recombinant Human Erythropoietin Produced in Chinese Hamster Ovary Cells”,Biochemistry, 26: 2633-2638 (1987).
Dorado et al., “Electrophoretic Behavior of Erythropoietin in Polyacrylamide Gel”,Biochem Medicine, 6: 238-245 (1972).
Dordal et al., “The Role of Carbohydrate In Erythropoietin Action”,Endocrinology, 116(6): 2293-2299 (1985).
Dube et al., “Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function”,J. Biol. Chem., 263(33): 17516-17521 (1988).
Egrie et al., “Characterization and Biological Effects of Recombinant Human Erythropoietin”,Immunobiol., 172: 213-224 (1986).
Egrie et al., “Pharmacokinetics of Recombinant Human Erythropoietin (rHuEpo) Administered to Hemodialysis (HD) Patients”,Kidney Intl., 33: (Abstract) p. 262 (1988).
Egrie et al., “The Role of Carbohydrate on the Biological Activity of Erythropoietin”,Glycoconjugate J., 10: (Abstract S7.7) p. 263 (1993).
Egrie et al, “Novel Erythropoiesis Stimulating Protein (NESP) Has a Longer Serum Half-Life and Greater in vivo Biological Activity than Recombinant Human Erythropoietin (rHuEPO)”Blood(Journal of the American Society of Hematology); 90(10) Suppl 1, Part 1; Abstract 243-I, pp. 56a-57a (1997).
Egrie et al., “Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)”,British Journal of Cancer, 84 (suppl. 1): 3-10 (2001).
Egrie et al., “Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)”,Nephrology Dialysis Transplantation, 16(suppl. 3): 3-13 (2001).
Elliott et al., “Characterization of Anti Erythropoietin Monoclonal Antibodies”,Blood, 74(Supp. 1), A 1228 (1989).
Elliott et al., “Secretion of Glycosylated Human Erythropoietin from Yeast Directed by thealpha-Factor Leader Region”,Gene, 79: 167-180 (1989).
Elliott et al., “An Immunological Approach to Determination of Protein Structure: Human Erythropoietin”,J. Cell. Biochem., Supp. 15G: Abstract No. R215, p. 192 (1991).
Elliott et al., “Structural Requirements for O-Linked Glycosylation of Human Erythropoietin”,Abstracts of the Protein Society, 5th Symp, Abstract No. M43 (1991).
Elliott et al., “Structural Requirements for O-Linked Glycosylation of Human Erythropoietin”, Abstract of Presentation at Keystone Symposium, Mar. 21-27, (1992).
Elliott et al., “Effect of Disulfide Bonds on the Structure and Activity of Erythropoietin”,J. Cell. Biochem., Supp. 17B,: Abstract No. E318, p. 89 (1993).
Elliott et al, “Structural Requirements for Addition of O-linked Carbohydrate to Recombinant Erythropoietin”,Biochemistry, 33(37): 11237-11245 (1994).
Elliott et al., “Isolation and Characterization of Conformation Sensitive Antierythropoietin Monoclo
Browne Jeffrey K.
Egrie Joan C.
Elliott Steven G.
Sitney Karen C.
Allen Marianne P
Amgen Inc.
DeBerry Regina M
Winter Robert B.
LandOfFree
Methods and compositions for the prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the prevention and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2693116